Quantum-Si Regains Nasdaq Compliance After Stock Surges Over 90% in One Month

Key highlights

• Nasdaq officially closed the bid price deficiency matter as of October 14, 2026
• Class A common stock maintained the required $1.00 minimum price for 10 straight days
• The company originally received the deficiency notice on July 23, 2026
• Share price has appreciated 91.72% over the last 30 days to reach $1.39
• Full-year 2026 revenue guidance is currently maintained at approximately $1.0 million

What Happened

On October 14, 2026, the Listing Qualifications Department of The Nasdaq Stock Market officially notified Quantum-Si Incorporated that it had regained compliance with the minimum bid price requirement. To satisfy Nasdaq Listing Rule 5450(a)(1), the company's Class A common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. The Nasdaq staff confirmed this milestone was achieved as of October 13, 2026. Consequently, the deficiency matter is now closed, ensuring the company maintains its continued listing on The Nasdaq Global Market.

Significance of Compliance

This resolution follows a deficiency notice received by the company on July 23, 2026, which indicated that the stock had traded below the $1.00 threshold for 30 consecutive business days. Quantum-Si was initially granted a 180-day grace period to rectify the situation. Regaining compliance well ahead of this deadline removes the immediate risk of delisting or a forced transfer to a lower-tier exchange. The company stated it will continue to monitor its closing bid price to ensure long-term adherence to Nasdaq listing standards and avoid future compliance notices that could trigger delisting proceedings.

Business Overview

Quantum-Si operates as a proteomics company focused on redefining protein analysis through single-molecule protein sequencing technology. Its proprietary benchtop platform is designed to provide researchers with real-time, kinetic-based detection, allowing for simplified workflows compared to traditional protein analysis methods. Recent developmental milestones include the detection of 19 amino acids in its Proteus program and data presentations at the World HUPO 2026 congress. The company aims to accelerate proteomic discovery by making high-resolution functional protein insights more accessible to laboratories globally through its next-generation sequencing kits and instrumentation.

Financial and Strategic Outlook

• Management reiterated full-year 2026 revenue guidance of approximately $1.0 million on August 13, 2026
• Total cash usage for the 2026 fiscal year is projected to be $93.0 million or less
• Adjusted operating expenses for 2026 are targeted at $98.0 million or less
• Commercial launch of the next-generation Proteus platform is scheduled for the second quarter of 2027
• The company reported a quarterly revenue of $0.344 million in its latest financial statement

Quantum-Si Inc · financial snapshot

Share price	$1.39
Market cap	$304M
Revenue (annual)	$2M
1-month price change	+91.72%
Sector	HealthcareMedical Devices

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.